Maxcyte, Inc. MXCT
Biotechnology: Commercial Physical & Biological Resarch · IPO 2021 · data as of November 13, 2026
Maxcyte, Inc. (MXCT) is a healthcare company listed in the US with a market value of about $123M. In the twelve months to September 30, 2026 it had revenue of $34M and net income of -$28M, a net margin of -81.4%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 5% a year, a 5-year average ROIC of -14%.
About Maxcyte
Maxcyte is listed in the US and classified in biotechnology: commercial physical & biological resarch, IPO year 2021. Revenue went from $22M in 2019 to $33M in 2025, growth of about 7.3% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 5% over three years (dilution for shareholders). It spends 63% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $34M | $33M | $39M | $41M | $44M | $34M | $26M | $22M |
| Net income | -$28M | -$45M | -$41M | -$38M | -$24M | -$19M | -$12M | -$13M |
| Free cash flow | -$21M | -$36M | -$29M | -$25M | -$33M | -$15M | -$11M | -$10M |
| EPS (diluted) | $-0.26 | $-0.42 | $-0.39 | $-0.37 | $-0.23 | $-0.21 | $-0.17 | $-0.23 |
| Net margin | -81.4% | -135.1% | -106.3% | -91.8% | -53.2% | -56.3% | -45.1% | -59.6% |
| ROIC | — | -21.6% | -18.0% | -15.2% | -8.0% | -5.3% | -21.9% | -72.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Maxcyte pay a dividend?
Not currently.
Is Maxcyte a good stock to buy?
We do not give buy or sell advice. Maxcyte scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.